Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates

Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session New Preclinical...

Related Keywords

New York ,United States ,Memorial Sloan Kettering Cancer Center ,Cambridge ,Cambridgeshire ,United Kingdom ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Kristinl Andrews ,Alexander Drilon ,Anupong Tangpeerachaikul ,Prnewswire Nuvalent Inc ,Md Memorial Sloan Kettering Cancer Center ,Nuvalent Inc ,Twitter ,Selection Of Third Development ,Nasdaq ,Preliminary Dose Escalation Data ,Preclinical Data ,Clinical Stage Candidate ,Third Development Candidate ,Potential Best In Class ,Positive Cancers ,Preclinical Characterization ,Host Conference Call ,Data Presentation ,Molecular Targeted ,New Drugs ,Plenary Session ,Poster Session ,Molecular Targeted Agents ,Nuvalent ,Nc ,Medical Pharmaceuticals ,Health Care Amp Hospitals ,Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,Trade Show News ,Roadcast Feed Annoucement ,